Contributions
Abstract: PB1433
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Diffuse large B-cell lymphoma (DLBCL) has significant clinico-histological and molecular heterogeneity but the frequency and prognostic significance of cytogenetic abnormalities on primary tissue has not been fully established.
Aims
To describe the the cytogenic and clinical data of DLBCL patients with nodal tissue subjected to conventional karyotyping and describe the effects of chromosomal abnormalities on survival outcomes.
Methods
All cases with cytogenetic studies performed on extramedullary tissue with a histopathological diagnosis of DLBCL made between 2003 and 2017 at ACT Pathology, Australian Capital Territory were included in this study. Histological diagnosis was made in accordance with the World Health Organisation classification criteria, and the lymphoma subtype and cell of origin using Han’s algorithm was recorded. Relevant clinical data was extracted from electronical medical records. Chromosome analysis was performed on fresh extramedullary tissue, whereby G-banding metaphases were analysed after a minimum of 24 hours of unstimulated culture. The karyotype was reported in accordance with the International System for Cytogenetic Nomenclature.
Results
In 78 patients identified, an abnormal karyotype (AK) was identified in 50 (64.1%) patients [39 patients (50%) with complex karyotype (CK) and 11 patients (14.1%) with 1-2 chromosomal abnormalities] and more frequent in transformed lymphoma (77.8%, with 55.6% having CK). AK was not associated with an inferior overall survival (OS) and progression-free survival (PFS) when compared to normal karyotype (5-year OS 78% vs 78.2%, p = 0.854 and 5-year PFS 72% vs 71.4%, p = 0.840). In univariate and multivariate analysis, AK, CK and frequent cytogenetic abnormalities were not found to be significant predictors of survival.
Conclusion
Chromosomal abnormalities in DLBCL detected on routine karyotyping are frequent but do not improve risk-stratification or alter treatment outcomes.
Keyword(s):
Abstract: PB1433
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Diffuse large B-cell lymphoma (DLBCL) has significant clinico-histological and molecular heterogeneity but the frequency and prognostic significance of cytogenetic abnormalities on primary tissue has not been fully established.
Aims
To describe the the cytogenic and clinical data of DLBCL patients with nodal tissue subjected to conventional karyotyping and describe the effects of chromosomal abnormalities on survival outcomes.
Methods
All cases with cytogenetic studies performed on extramedullary tissue with a histopathological diagnosis of DLBCL made between 2003 and 2017 at ACT Pathology, Australian Capital Territory were included in this study. Histological diagnosis was made in accordance with the World Health Organisation classification criteria, and the lymphoma subtype and cell of origin using Han’s algorithm was recorded. Relevant clinical data was extracted from electronical medical records. Chromosome analysis was performed on fresh extramedullary tissue, whereby G-banding metaphases were analysed after a minimum of 24 hours of unstimulated culture. The karyotype was reported in accordance with the International System for Cytogenetic Nomenclature.
Results
In 78 patients identified, an abnormal karyotype (AK) was identified in 50 (64.1%) patients [39 patients (50%) with complex karyotype (CK) and 11 patients (14.1%) with 1-2 chromosomal abnormalities] and more frequent in transformed lymphoma (77.8%, with 55.6% having CK). AK was not associated with an inferior overall survival (OS) and progression-free survival (PFS) when compared to normal karyotype (5-year OS 78% vs 78.2%, p = 0.854 and 5-year PFS 72% vs 71.4%, p = 0.840). In univariate and multivariate analysis, AK, CK and frequent cytogenetic abnormalities were not found to be significant predictors of survival.
Conclusion
Chromosomal abnormalities in DLBCL detected on routine karyotyping are frequent but do not improve risk-stratification or alter treatment outcomes.
Keyword(s):